Il y a 4 ans sévissait la plus dévastatrice épidémie d’Ebola en Afrique de l’Ouest. Les reporters de TV5 Monde sont retournés en Guinée, pays du patient zéro. La population est encore traumatisée par un fléau qui a tué 11 000 personnes, et contre lequel la seule défense qui existe, est un vaccin expérimental.
The number of plague cases has been steadily increasing over the past 30 years and Madagascar has gone through an unprecedented epidemic episode in 2017. In response, REACTing from Inserm, the Pasteur Institute of Madagascar and the International Network of the Institut Pasteur organized, on 9 and 10 July 2018, an international workshop to define research priorities on this disease.
Experimental treatments are being considered to cope with the current Ebola outbreak in the Democratic Republic of Congo. An experimental vaccine is already being administered.
In France, considerations around experimental treatments are notably lead within the REACTing platform of Inserm, in collaboration with the research institutes grouped under the Alliance for Life Sciences and Health (Aviesan).
The INRB of Kinshasa and Inserm have identified the Ebola Zaire strain as responsible for the epidemic currently raging in the DRC.
“Our experience in Guinea during the 2014 Ebola outbreak, the REACTing platform under the responsibility of Prof. Yazdanpanah, and the North / South collaborations put in place allowed us to better prepare and respond quickly”, says Pr Yves Lévy, CEO of Inserm.
A study conducted in pregnant women and their unborn children during the Zika epidemic in the French territories in the Americas, permitted researchers from Inserm, Institut Pasteur and the University Hospital of Guadeloupe to accurately estimate the risk of severe neurological complications in babies. They have also determined that the first trimester of pregnancy is the period with the highest risk. While the overall risk is 7%, this rises to 12.7% – i.e. more than 1 in 10 children – if infection occurs during the first 3 months of pregnancy. Published in the New England Journal of Medicine.
The Partnership for Research on Ebola VACcination (PREVAC) immunisation study began 1 year ago, when the Ebola virus was re-emerging in the DRC. Thanks to more than 2,000 adults and children in the study in Guinea and Liberia, this international clinical trial is evaluating the safety and immunogenicity of two potential vaccines against the Ebola virus. The results will be decisive in preventing a new epidemic.